TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: joint pain intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: patient global assessment
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: post-EST bleeding
Endpoint domain: Adverse events/effects
Primary endpoint: aerobic energy contribution
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: O2 deficit
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: muscle lactate accumulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: perceived intensity of dyspnea
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of unintended breaks during exercise
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Area under the concentration-time curve (AUC(tau,ss))
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum concentration in steady state (C(max,ss))
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adverse events attributed to bosentan
Endpoint domain: Adverse events/effects
Primary endpoint: HIV-free survival at 24 months
Endpoint domain: Mortality/survival
Primary endpoint: Mortality by 24 months in HIV-infected children
Endpoint domain: Mortality/survival
Primary endpoint: Switch to hypomania or mania
Endpoint domain: Adverse events/effects
Primary endpoint: Limb salvage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: GSH levels in blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Natural killer cytotoxicity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: One-year disease-free survival
Endpoint domain: Mortality/survival
Primary endpoint: Toxicity (all grades)
Endpoint domain: Adverse events/effects
Primary endpoint: Composite end point
Endpoint domain: Mortality/survival
Primary endpoint: Serum MMP‐2 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum MMP‐9 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: diagnostic accuracy for heart failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: inflammation rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Variability-adjusted BP change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Urinary sodium-to-creatinine ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: perceived risk
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: intentions to pursue GC
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: IES avoidance subscale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Enrollment rates of worksites
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Patterns of treatment response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement of endothelial function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Improvement of microcirculation indices
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Physical activity time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: leg A‐V glucose concentration gradient
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Reduction in BEHAVE-AD aggression scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: exercise heart rate reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: plasma timolol concentration increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Fracture incidence of NiTi‐RIs
Endpoint domain: Adverse events/effects
Primary endpoint: Achieved undetectable viral load (VL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Objective cure rate for stress urinary incontinence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Subjective report of stress urinary incontinence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: balance measures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: right ankle tactile sensation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: transient return of depressive symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: increase in regional cerebral glucose utilization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Complete continence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Operative time and hospital stay
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: pHi measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: UFOV performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Stress
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Acceptance
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Aldrete score of nine or more
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average number of hot flushes/day
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cholesterol levels (total, LDL, HDL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Physical Health-Related Quality of Life (HRQL)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: maximal voluntary contraction strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of tacrolimus bioassays within target range
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Average overall adherence to treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: total disability
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: level of pain relief
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of participants drinking within low-risk guidelines
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean weekly alcohol intake reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PC 20
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Rate of successful abortions within 24 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of complete abortion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average cost per treatment
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Self-efficacy postintervention
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Overall adjusted concordance
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: externalizing behavior problems
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Improvements in main symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Colonoscopic scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Histopathology of the colonic membrane
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 2-year overall survival (OS) rate of un-resectable patients
Endpoint domain: Mortality/survival
Primary endpoint: CAL gain (Clinical Attachment Level)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient satisfaction (OHIP-49 sum score)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: postoperative surgical site infection (SSI) rates
Endpoint domain: Adverse events/effects
Primary endpoint: Disease control rate at 6 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall survival at 3 and 5 years
Endpoint domain: Mortality/survival
Primary endpoint: Cancer-specific survival at 3 and 5 years
Endpoint domain: Mortality/survival
Primary endpoint: Disease-free survival at 3 and 5 years
Endpoint domain: Mortality/survival
Primary endpoint: Response to treatment based on genotype
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Excess weight lost (EWL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in outpatient clinical work
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: less unprotected sex with non‐monogamous partners
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: mean reduction in hemoglobin level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: TXA-related cost
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Major curve correction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: working memory capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: efficiency of mental set shifting and flexibility
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Hemoglobin (Hb)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum Ferritin (SF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: heart rate response variation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: cost of treatment
Endpoint domain: Resource use
Primary endpoint: tremor incidence
Endpoint domain: Adverse events/effects
Primary endpoint: Reduction in antiparkinsonian threshold dose of IV levodopa
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Achieving PTH level of 300 pg/mL or lower
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Efficacy of ET
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Performance on series completion tasks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: process of change
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: smoking temptation
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: stage change transition
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Percentage of feces in toilet
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: CPAP failure
Endpoint domain: Adverse events/effects
Primary endpoint: nasal trauma (any grade)
Endpoint domain: Adverse events/effects
Primary endpoint: bronchopulmonary dysplasia
Endpoint domain: Adverse events/effects
Primary endpoint: Weight regain after 12 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time needed for clamming of the internal carotid artery
Endpoint domain: Surgical and medical procedures outcomes
Primary endpoint: Average length of surgeries
Endpoint domain: Surgical and medical procedures outcomes
Primary endpoint: Rate of distal intimal fixation
Endpoint domain: Surgical and medical procedures outcomes
Primary endpoint: Rate of CMV infection
Endpoint domain: Adverse events/effects
Primary endpoint: Shortening of hypokinetic wall segments
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Pharmacokinetic parameters of Bbr
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: episodes of clinical UTI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: A(H1N1)pdm09-specific antibody responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: CD4(+) T-cell responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Memory B-cell responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Cumulative incidence of BOS Grade ≥1 at 3 years
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of postoperative pulmonary fistula
Endpoint domain: Adverse events/effects
Primary endpoint: Event rates with clopidogrel vs placebo
Endpoint domain: Mortality/survival
Primary endpoint: incidence of numbness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: temperature recovery time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: development of interosseous arteries
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: alfentanil clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: fentanyl clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean number of inflammatory acne lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Mean number of noninflammatory acne lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Mean value of Michaelson's acne severity index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Reduction in subcutaneous fat
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in intra-abdominal fat
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of gingival invaginations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severity of gingival invaginations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pre-exercise antioxidant status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Amount of oral bacteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: acne improvement score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Risk of infection-related cancer
Endpoint domain: Mortality/survival
Primary endpoint: Risk of infection-unrelated cancer
Endpoint domain: Mortality/survival
Primary endpoint: Sensitivity and specificity of the FLUSH test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Dental inclination
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: blood loss/cm(2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients advised to stop smoking
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of urine samples negative for opiates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Opiate craving
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Postoperative myocardial infarction
Endpoint domain: Mortality/survival
Primary endpoint: Composite of RAO and symptomatic RAS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rotational stability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visual outcomes (UDVA, CDVA, DCIVA, DCNVA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: self-efficacy for weight loss
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: expiratory flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: lung mechanics
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: mean number of spotting days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: NTGM (Non-Traditional Glycemic Markers)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall antibiotic use
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Incidence of influenza-related LRTCs resulting in antibiotic therapy
Endpoint domain: Adverse events/effects
Primary endpoint: Hospitalization for any cause
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Median estimated glomerular filtration rate at 3 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: IPT completion rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: dropout rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in maximum % response to ACh
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Rate of conversion of AF to SR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: QT-interval prolongation
Endpoint domain: Adverse events/effects
Primary endpoint: Lowering systolic pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Content of serum ACE
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Content of plasma ET
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Total numbers of CD4 and CD8 T-lymphocytes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Prevention of respiratory tract infections
Endpoint domain: Adverse events/effects
Primary endpoint: Load to tuberosity fixation failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Mean fracture displacement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: wound hyperthermia
Endpoint domain: Adverse events/effects
Primary endpoint: Complete ablation of cysts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total cured rate
Endpoint domain: Mortality/survival
Primary endpoint: Visualization of the Z-line
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: GCF t-PA levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response rate of chemotherapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recurrence outside the irradiated field
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Right ventricular fractional area change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Right ventricular indexed end‐diastolic volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Forced expiratory volume in first second (FEV1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: quality of pain treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: verbal aggression incidents
Endpoint domain: Adverse events/effects
Primary endpoint: leave violations incidents
Endpoint domain: Adverse events/effects
Primary endpoint: substance use incidents
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of patients who are responders
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total pain intensity response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Times to meaningful and total pain relief
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: frequency of embolic signals
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Detection of GEP neuroendocrine tumor sites
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Somatostatin receptor-positive lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Peak Drug Liking
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Histologic depth score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnostic adequacy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: use of albuterol MDI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: patients' opinions of overall effectiveness
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: 10-year predicted CHD risk
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: follow-up time with bacteriuria
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: duration of bacteriuria
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: carriage of unique isolates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Perception of patient competence
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: response to intensive intervention
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Major improvement after 3 days
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Severe diarrhea at Day 3
Endpoint domain: Adverse events/effects